A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Equillium, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 300,400 shares of EQ stock, worth $270,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300,400
Previous 209,200 43.59%
Holding current value
$270,360
Previous $483,000 57.14%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.66 - $2.33 $60,192 - $212,496
91,200 Added 43.59%
300,400 $207,000
Q1 2024

May 13, 2024

SELL
$0.73 - $3.0 $100,959 - $414,900
-138,300 Reduced 39.8%
209,200 $483,000
Q4 2023

Feb 13, 2024

BUY
$0.48 - $0.74 $26,020 - $40,114
54,209 Added 18.48%
347,500 $251,000
Q3 2023

Nov 14, 2023

SELL
$0.72 - $0.9 $71,236 - $89,046
-98,940 Reduced 25.22%
293,291 $217,000
Q2 2023

Aug 11, 2023

BUY
$0.49 - $0.79 $173,230 - $279,289
353,531 Added 913.52%
392,231 $294,000
Q1 2023

May 12, 2023

BUY
$0.56 - $1.24 $9,072 - $20,088
16,200 Added 72.0%
38,700 $28,000
Q4 2022

Feb 13, 2023

BUY
$0.83 - $2.26 $4,399 - $11,977
5,300 Added 30.81%
22,500 $24,000
Q3 2022

Nov 14, 2022

BUY
$1.93 - $3.14 $1,351 - $2,198
700 Added 4.24%
17,200 $38,000
Q2 2022

Aug 12, 2022

BUY
$1.69 - $3.26 $27,885 - $53,790
16,500 New
16,500 $34,000
Q1 2021

May 13, 2021

SELL
$5.03 - $10.5 $208,790 - $435,844
-41,509 Closed
0 $0
Q4 2020

Feb 10, 2021

SELL
$3.48 - $6.58 $229,123 - $433,227
-65,840 Reduced 61.33%
41,509 $222,000
Q3 2020

Nov 13, 2020

BUY
$2.78 - $26.5 $20,016 - $190,800
7,200 Added 7.19%
107,349 $619,000
Q2 2020

Aug 13, 2020

BUY
$2.34 - $3.53 $92,902 - $140,148
39,702 Added 65.68%
100,149 $295,000
Q1 2020

May 14, 2020

BUY
$2.3 - $5.5 $81,436 - $194,738
35,407 Added 141.4%
60,447 $164,000
Q4 2019

Feb 13, 2020

BUY
$3.0 - $5.0 $75,120 - $125,200
25,040 New
25,040 $85,000

Others Institutions Holding EQ

About Equillium, Inc.


  • Ticker EQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,352,100
  • Market Cap $30.9M
  • Description
  • Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...
More about EQ
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.